Ambit Biosciences signs drug-development deal with Astellas

12/23/2009 | North County Times (Temecula, Calif.)

Astellas Pharma will pay Ambit Biosciences $40 million upfront and as much as $350 million in milestone fees as part of a drug-development collaboration. The partnership covers an acute myeloid leukemia treatment, which is in midstage trials, and other drugs that target an enzyme called FLT3 kinase.

View Full Article in:

North County Times (Temecula, Calif.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN